TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$62.76
−3.06%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- $0.05
- Revenue estimate
- $195.7M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.37
- EPS estimate
- -$0.13
- Revenue actual
- $169.6M
- Revenue estimate
- $157.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- -3.6%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $76
- PT range
- $70 – $85
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.13 | -$0.37 | Miss -174.79% | $169.6M |
| May 4, 2026 | -$0.30 | -$0.39 | Miss -30.00% | $127.2M |
| Feb 19, 2026 | $0.03 | $0.03 | In line | $129.7M |
| Oct 30, 2025 | -$0.31 | $0.28 | Beat 190.32% | $164.9M |
| May 1, 2025 | -$0.55 | -$0.47 | Beat 14.55% | $81.7M |
| Feb 20, 2025 | -$0.58 | -$0.73 | Miss -25.86% | $74.8M |
| Oct 31, 2024 | -$0.70 | -$0.70 | In line | $62.9M |
| Aug 1, 2024 | -$0.87 | -$0.90 | Miss -3.45% | $54.1M |
| Feb 15, 2024 | -$1.27 | -$1.16 | Beat 8.66% | $45.1M |
| Aug 3, 2023 | -$1.16 | -$1.13 | Beat 2.59% | $59.7M |
| May 4, 2023 | -$1.18 | -$1.27 | Miss -7.63% | $57.0M |
| Feb 23, 2023 | -$1.04 | -$1.03 | Beat 0.96% | $55.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026